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Summary: The influence of the fungoid undecapeptide cyclosporin A 
(CyA) on PGE? release from cultured rat aortic smooth muscle 
cells was investigated in this study. We found that C~A time and 
concentration dependently (ED,,: 500 rig/ml) inhibited PGE2 
release from the cells. CyA attenuated both basal and PGEz 
release evoked by angiotensin II (10‘10-10~6M), arginine 
vasopressine (lO"" -10-6M)and ionomycin (lo-'-IO-'M). CyA 
(lpg/ml) did not affect the conversion of exogenous arachidonic 
acid (IpM) into PGE,. The inh,ibitory effect of CyA was 
neutralized by high concentrations of the calcium ionophore 
ionomycin (> 3x10TbM). Taken together our results indicate that 
CyA inhibits both basal and vasoconatrictor evoked PGE, release 
from vascular smooth muscle by impairing the availability of free 
arachidonic acid rather than by inhibiting the conversion of 
arachidonic acid into PGEZ. - o 1987 Academic Press, Inc. 
The fungoid undecapeptide cyclosporin A (CyA) (1) is a potent 
inhibitor of interleukin-2 production in T-lymphocytes(2). Due to 
this action CyA has become a powerful tool in the management of 
allograft rejection. However, its usefulness is limited by severe 
adverse reactions. Thus CyA has detrimental effects on blood 
vessels causing arteriolopathy and enhanced arteriolar 
constriction resulting in systemic hypertension and reduction of 
renal blood flow(cf 3). The mechanism by which CyA alters 
arteriolar function is not yet understood. It has been observed 
that CyA impairs vascular prostaglandin formation in viva(4) and 
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endothelial prostacyclin formation in vitro(5) and that exogenous 
prostaglandins are capable to protect from the detrimental 
vascular effects of ~y~(6,7). Vasodilatory prostaglandins, in 
particular PGEP, are produced by vascular smooth muscle 
cells(VSMC) in response to vasoconstrictive hormones. Since this 
modulatory reaction is important for the regulation of VSMC 
function (8) the present study was done to find out whether CyA 
alters PGEI formation in response to vasoconstrictors in cultured 
VSMC from rat aorta. 
Materials and Methods 
cell culture: Cultures of VSMC from rat aorta were prepared and 
handled as described previously (9). The cells were grown on 24- 
well plates in RPM1 1640 medium (supplemented with 10% FBS, 25 mM 
Hepes, 1 U/ml insulin and penicillin/streptomycin). Subconfluent 
cultures between the second and fourth passage were used for the 
experiments. 
experiments: Cells were preincubated with normal cell culture 
medium containing CyA for different times (0.15 - 24 hours) at a 
single concentration (Ipg/ml) or at different concentrations 
(0.01 - 10 ug/ml) for a single time interval (3 hours). After 
preincubation the multiwell plates were placed on a heater 
maintaining them at 37"~. The medium was removed and the cells 
were quickly washed twice with prewarmed L-15 medium (without 
supplementation). The cells were then incubated with 0.2ml of 
this medium with or without agents. After five minutes the medium 
was removed and immediately centrifuged at 4000,g for five 
minutes. The supernatant was frozen in Liquid nitrogen and stored 
at -80°C until assay of PGE,. Concentrations of PGE, were 
determined with a commercially available radioimmunoassay (New 
England Nuclear). The cells were lysed in IN NaOH and cellular 
protein was determined according to the method of Lowry (10) 
using bovine serum albumin as a standard. 
Determination of fractional arachidonic acid release: 
Cells were prelabelled with O.ZpCi/ml of "C-arachidonic acid 
(New England Nuclear) in DMEM medium supplemented with fatty acid 
free bovine serum albumin for 24 hours. CyA (lOpg/ml) was added 
during the last three hours of the labelling period. Afterwards 
the cells were thoroughly washed with L-15 medium and incubated 
with this medium (with and without angiotensin II, IO-'M) for 15 
minutes. The supernatant then was removed and the cells were 
lysed by the additipn of IN NaOH. Fractional AA-release was 
calculated from the ratio of radioactivity in the supernatant 
over the sum of radioactivities present in cells and supernatant. 
chemicals: CyA as a pure powder was a generous gift from the 
Sandoz Company (Basle,Switzerland). Arginine vasopressin (PVP), 
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angiotensin II (AII)and arachidonic acid (AA) were purchased from 
Sigma, ionopycin was obtained from Calbiochem. Stocks of CyA 
(20mg/ml), ionomycin (10 mM) and arachidonic acid (3mM) were 
prepared in pure ethanol. Further dilutions were made in L-15 
medium. 
Results 
In vivo, the effects of CyA occur in a time and concentration 
dependent fashion. In order to find out whether CyA affects PGEi 
from VSMC at all, the cells were preincubated with a single 
concentration of CyA (lpg/ml) for different times. PGE, was 
stimulated with a submaximal concentration of the calcium 
ionophore ionomycin (IO-'M). The results shown in table I 
indicate that CyA time dependently inhibited ionomycin evoked 
PGE, release. Already after one hour of preincubation the 
inhibitory effect of CyA on PGE2 release was maximal and this 
effect of CyA was not altered by longer incubation. 
Further experiments were therefore done after a preincubation 
period of three hours with CyA as a rule. In figs. 1 and 2 the 
effect of CyA on PGE? release evoked by the vasoconstrictive 
hormones AVP and AI1 are shown. It is evident that CyA already 
diminished basal PGE, release. Taking all experiments together 
the ED, o value for the inhibitory action of CyA on basal 
PGE,release was estimated to around 500 rig/ml. The figures 
further show that CyA also attenuated PGE, release evoked by AVP 
and AII. Obviously CyA did not shift the dose-response curves for 
both hormones. 
Table 1 
POE? release from VSMC in response to ionomycin (1pM) after 
various times of preincubation with CyA (lpg/ml) 
PGE, (ng/min per mg cellular protein) 
time (h) 0.15 0.5 1 3 5 24 
control 5.2t0.4 5.0t0.2 5.5t0.7 4.9t0.6 4.5kO.2 4.2~0.4 
CyA (lug/ml) 4.9iO.5 3.9kO.6 2.4kO.5 2.5t0.3 2.3kO.6 2.0~0.3 
CyA/co 0.95 0.78 0.44 0.52 0.50 0.48 
Data are mean + SEM of quadruplicates. Basal PGE, release was 
1.2+0.2 ng/min per mg cellular protein. 
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Figure 1. Effect of CyA on PGE2 release fr6m VSMC in response to arginine 
vasopressin (AVP). Preincubation time with CyA was three hours. 
Data are mean + SEM of five experiments. 
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Figure 2. Effect of CyA on PGEl release from VSMC in response to 
angiotensin II (AII). Data are mean + SEM of five experiments. 
545 
Vol. 147, No. 2,1987 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 
Table 2 
Effect of CyA on PGE, release from VSMC in presence of exogenous 
arachidonic acid (IpM) 
CYA (w/ml) 0 0.01 0.1 1 .o 10.0 
PGE,(ng/min x mg)l0.4+2.1 14.4Ll .o 10.6k2.5 13.5&l .4 12.9kO.9 
Data are mean + SEM of five experiments. Basal PGE2 release was 
2.0+0.3 ng/min x mg). 
Cellular prostaglandin formation in general is determined by the 
activity of phospholipases which liberate the substrate 
arachidonic acid (AA) one the one hand and the conversion rate 
of AA into prostaglandins by cyclooxygenase activity on the other 
(11). To examine whether CyA could affect the conversion of AA by 
interference with cyclooxygenase activity, PGE, formation in 
presence of exogenous AA (IuM) was determined. The results (table 
II) clearly show that the conversion of AA into PGE, was not 
altered by CyA. 
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Figure 3. Effect of CyA on PGE, release from VSHC in response to ionomycin. 
Data are mean of five experiments. 
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The activity of phospholipases, in particular of phospholipase A, 
is calcium dependent (12,13). To find out out whether or not CyA 
could affect phospholipase activity, PGEz formation in presence 
of the calcium ionophore ionomycin was measured. The results 
(fig.3) show that CyA inhibited ionomycin evoked PGE, release up 
to a concentration of around 10e6M. However, at high 
concentrations of ionomycin (>3xlO“M) no inhibitory effect of 
CyA on prostaglandin formation could be observed. Phospholipase 
activity was further assessed by determination of the fractional 
"C-arachidonic acid release from prelabelled VSMC. Fractional 
AA-release within 15 minutes from control cells was 1.6 +/- 0.2 % 
(mean+/-SEM;n=5). In presence of angiotensin II (IO-'M) this 
figure was raised to 8.2 +/- 0.4%. After 3 hours of preincubation 
with CyA (lOpg/ml) fractional AA-release in presence of A II was 
2.9 +/- 0.7 %. 
Discussion 
This study was undertaken to determine if CyA alters PGE, 
production by rat aortic smooth muscle cells. We found that CyA 
inhibited both basal and vasoconstrictor evoked PGEz formation 
by a factor of 1.5 - 2 in a concentration dependent fashion. The 
ED, o value was estimated to be around 500ng/ml and this figure is 
in the range of conventional therapeutic levels attained in serum 
in vivo in man and laboratory animals (3). Concerning the 
mechanism by which CyA could inhibit PGE, formation our results 
indicate that CyA does not inhibit cyclooxygenase activity, 
because the conversion of exogenous arachidonic into PGE, was not 
altered by CyA (table II). Thus it seems likely that CyA reduced 
the availability of free arach'Ilc;cic acid (AA). The level of free 
AA is determined by the rate of reacyclation by the activity of 
acyl-transferases on the one hand and by the rate of deacylation 
by the activity of phospholipases (PLA) on the other (11). The 
observations that PGE, release in response to specific, receptor- 
mediated (in the case of AVP and AII) and unspecific (in the case 
of ionomycin) stimulation of PLA activity was blunted by CyA 
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argue in favour of an interference of CyA with the liberation of 
AA. Impaired deacylation of AA from phospholipids could result 
from a reduction of AA stores or from a functional inhibition of 
PLA activity. From the findings that impaired angiotensin II 
induced AA release and that high concentrations of ionomycin were 
able to overcome the inhibitory effect of CyA on PGE, release 
(fig.3) we may infer that CyA acts by inhibiting PLA activity 
rather than by depleting pools for AA. This conclusion fits with 
recent findings demonstrating that CyA inhibits phospholipase 
activity in macrophages (14) and in renal mesangial cells (15). 
Our observation that the inhibitory action of CyA on PGE, 
formation was modulated by the calcium ionophore could indicate 
that CyA affects the interaction between calcium and PLA. It 
might be of relevance in this context that the activation of PLA, 
by calcium appears to be mediated by calmodulin (16,17). For T- 
lymphocytes evidence was recently provided that CyA binds to 
calmodulin and antagonizes calmodulin activity (18). Under the 
assumption that CyA binds to calmodulin also in vascular smooth 
muscle cells a calmodulin antagonism could be the mechanism by 
which CyA inhibits phospholipase activtity and in consequence 
PGE, formation. To prove this hypothesis remains a task for 
future research. 
In summary our results indicate that attenuation of PGE, release 
could be one pathophysiologic mechanism by which CyA alters 
vascular smooth muscle cell function. 
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